RxDoctor Payments Data

Lisa Stephens, PA

Physician Assistant · Clearfield, UTNPI 1831590769

Payments from drug & device makers

$5,347in general payments, 2019–2025

Across 284 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Biohaven Pharmaceuticals, Inc.$914
  • Amgen$265
  • Lilly USA, LLC$250
  • AstraZeneca$212
  • Boehringer Ingelheim$191
  • plus $2K from 34 others

What the payments were for

  • Consulting fees$80015%
  • Food & beverage$4,45083%
  • Education$972%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,347 in reported general payments places this provider in the 90th percentile of 1,543 physician assistant providers in Utah.

See all physician assistant providers in Utah

Medicare billing

Part B allowed, 2024
$11,013
Medicare patients
28
Services billed
205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban14$10,144
OzempicSemaglutide11$8,716
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$6,789
Bupropion XlBupropion Hcl22$824
Estradiol12$682
Levothyroxine Sodium68$640
Duloxetine Hcl25$595
Atorvastatin Calcium51$495
Rosuvastatin Calcium32$356
Trazodone Hcl26$341
Omeprazole23$323
Simvastatin23$299
Losartan Potassium33$287
Fluoxetine Hcl13$250
Potassium Chloride16$241

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$177$10,14414 claims
Novo NordiskOzempic$190$8,71611 claims
Almatica Pharma LLCSertraline Hcl$17$8919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,543 physician assistant providers in Utah.

Other physician assistant in Clearfield

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →